GlassScriptPhysician profile
Jack C Huang
NPI 1003802380
$55,210.80
in general payments reported to CMS, 2019-2025
41 companies · $5,954 in 2025
The $5,954 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $373 · 2021: $675 · 2022: $1,858 · 2023: $2,013 · 2024: $43K · 2025: $5,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $11K · Travel and Lodging: $6,043 · Education: $38.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,950.00 |
| Food and Beverage | $10,845.74 |
| Travel and Lodging | $6,042.99 |
| Education | $38.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42,073.08 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,823.22 | 2019-2025 | |
| Janssen Biotech, INC. | $1,656.26 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $833.00 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $759.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $651.57 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $625.62 | 2019-2025 | |
| Celgene Corporation | $542.31 | 2021-2024 | Zeposia |
| Genzyme Corporation | $469.21 | 2022-2025 | |
| Medtronic, INC. | $458.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $457.79 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $449.20 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $332.54 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $312.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Echosens North America, INC. | $285.99 | 2019-2023 | Fibroscan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.